Kevin Alan Lobb

Prof. Kevin Alan Lobb

Rhodes University
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2018 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
Taj MohammadTaj Mohammad
Taj Mohammad
Faez Iqbal KhanFaez Iqbal Khan
Faez Iqbal Khan
Kevin Alan LobbKevin Alan Lobb
Kevin Alan Lobb
Asimul IslamAsimul Islam
Asimul Islam
Faizan AhmadFaizan Ahmad
Faizan Ahmad
Md. Imtaiyaz HassanMd. Imtaiyaz Hassan
Md. Imtaiyaz Hassan
Microtubule affinity-regulating kinase 4 (MARK4) has recently been identified as a potential drug target for several complex diseases including cancer, diabetes and neurodegenerative disorders. Inhibition of MARK4 activity is an appealing therapeutic option to treat such diseases. Here, we have performed structure-based virtual high-throughput screening of 100,000 naturally occurring compounds from ZINC database against MARK4 to find its potential inhibitors. The resulted hits were selected, based on the binding affinities, docking scores and selectivity. Further, binding energy calculation, Lipinski filtration and ADMET prediction were carried out to find safe and better hits against MARK4. Best 10 compounds bearing high specificity and binding efficiency were selected, and their binding pattern to MARK4 was analyzed in detail. Finally, 100 ns molecular dynamics simulation was performed to evaluate; the dynamics stability of MARK4-compound complex. In conclusion, these selected natural compounds from ZINC database might be potential leads against MARK4, and can further be exploited in drug design and development for associated diseases.

19 June 2015 in Journal of Cheminformatics
Verified
Journal Article
Open access
PDF file
RHRowan Hatherley
Rowan Hatherley
DBDavid K Brown
David K Brown
TMThommas Musyoka
Thommas Musyoka
DPDavid L Penkler
David L Penkler
NFNgonidzashe Faya
Ngonidzashe Faya
Ozlem Tastan BishopOzlem Tastan Bishop
Ozlem Tastan Bishop
Natural products (NPs) are important to the drug discovery process. NP research efforts are expanding world-wide and South Africa is no exception to this. While freely-accessible small molecule databases, containing compounds isolated from indigenous sources, have been established in a number of other countries, there is currently no such online database in South Africa. The current research presents a South African natural compound database, named SANCDB. This is a curated and fully-referenced database containing compound information for 600 natural products extracted directly from journal articles, book chapters and theses. There is a web interface to the database, which is simple and easy to use, while allowing for compounds to be searched by a number of different criteria. Being fully referenced, each compound page contains links to the original referenced work from which the information was obtained. Further, the website provides a submission pipeline, allowing researchers to deposit compounds from their own research into the database. SANCDB is currently the only web-based NP database in Africa. It aims to provide a useful resource for the in silico screening of South African NPs for drug discovery purposes. The database is supported by a submission pipeline to allow growth by entries from researchers. As such, we currently present SANCDB the starting point of a platform for a community-driven, curated database to further natural products research in South Africa. SANCDB is freely available at https://sancdb.rubi.ru.ac.za/ .

1 February 2018 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
FNFarha Naz
Farha Naz
Faez Iqbal KhanFaez Iqbal Khan
Faez Iqbal Khan
Taj MohammadTaj Mohammad
Taj Mohammad
PKParvez Khan
Parvez Khan
SMSaaliqa Manzoor
Saaliqa Manzoor
Md. Imtaiyaz HassanMd. Imtaiyaz Hassan
Md. Imtaiyaz Hassan

31 March 2016 in Scientific Reports
Verified
Journal Article
Open access
TMThommas Musyoka
Thommas Musyoka
AKAquillah Kanzi
Aquillah Kanzi
Kevin Alan LobbKevin Alan Lobb
Kevin Alan Lobb
Ozlem Tastan BishopOzlem Tastan Bishop
Ozlem Tastan Bishop
Identification of potential drug targets as well as development of novel antimalarial chemotherapies with unique mode of actions due to drug resistance by Plasmodium parasites are inevitable. Falcipains (falcipain-2 and falcipain-3) of Plasmodium falciparum, which catalyse the haemoglobin degradation process, are validated drug targets. Previous attempts to develop peptide based drugs against these enzymes have been futile due to the poor pharmacological profiles and susceptibility to degradation by host enzymes. This study aimed to identify potential non-peptide inhibitors against falcipains and their homologs from other Plasmodium species. Structure based virtual docking approach was used to screen a small non-peptidic library of natural compounds from South Africa against 11 proteins. A potential hit, 5α-Pregna-1,20-dien-3-one (5PGA), with inhibitory activity against plasmodial proteases and selectivity on human cathepsins was identified. A 3D similarity search on the ZINC database using 5PGA identified five potential hits based on their docking energies. The key interacting residues of proteins with compounds were identified via molecular dynamics and free binding energy calculations. Overall, this study provides a basis for further chemical design for more effective derivatives of these compounds. Interestingly, as these compounds have cholesterol-like nuclei, they and their derivatives might be well tolerated in humans.

1 November 2018 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
ABAnam Beg
Anam Beg
Faez Iqbal KhanFaez Iqbal Khan
Faez Iqbal Khan
Kevin Alan LobbKevin Alan Lobb
Kevin Alan Lobb
Asimul IslamAsimul Islam
Asimul Islam
FAFaizan Ahmad
Faizan Ahmad
Md. Imtaiyaz HassanMd. Imtaiyaz Hassan
Md. Imtaiyaz Hassan
Calcium/calmodulin-dependent protein kinase IV (CAMKIV) is associated with many diseases including cancer and neurodegenerative disorders and thus being considered as a potential drug target. Here, we have employed the knowledge of three-dimensional structure of CAMKIV to identify new inhibitors for possible therapeutic intervention. We have employed virtual high throughput screening of 12,500 natural compounds of Zinc database to screen the best possible inhibitors of CAMKIV. Subsequently, 40 compounds which showed significant docking scores (−11.6 to −10.0 kcal/mol) were selected and further filtered through Lipinski rule and drug likeness parameter to get best inhibitors of CAMKIV. Docking results are indicating that ligands are binding to the hydrophobic cavity of the kinase domain of CAMKIV and forming a significant number of non-covalent interactions. Four compounds, ZINC02098378, ZINC12866674, ZINC04293413, and ZINC13403020, showing excellent binding affinity and drug likeness were subjected to molecular dynamics simulation to evaluate their mechanism of interaction and stability of protein-ligand complex. Our observations clearly suggesting that these selected ligands may be further employed for therapeutic intervention to address CAMKIV associated diseases. Communicated by Ramaswamy H. Sarma

1 December 2010 in Tetrahedron Letters
Verified
Journal Article
Closed access
TOTemitope O. Olomola
Temitope O. Olomola
RKRosalyn Klein
Rosalyn Klein
Kevin Alan LobbKevin Alan Lobb
Kevin Alan Lobb
YSYasien Sayed
Yasien Sayed
PKPerry T. Kaye
Perry T. Kaye